Progressive Supranuclear Palsy (PSP)
19
5
5
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.3%
1 terminated out of 19 trials
92.3%
+5.8% vs benchmark
11%
2 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (19)
Synaptic Loss in Multiple System Atrophy
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
The CurePSP Genetics Program
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
ADDIA Proof-of-Performance Clinical Study
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Human CNS Tau Kinetics in Tauopathies
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Safety Study of TPI-287 to Treat CBS and PSP
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies